Stavudine

Stavudine

SCHEMBL1674560

Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O.Cc1cn([C@]2(F)O[C@H](CO)[C@@H](O)C2(F)F)c(=O)[nH]c1=O

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

pol

The experimentally established mechanism targets of Stavudine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.67
LMNA P02545 1/20 0.67
ALB P02768 1/20 0.67
POLB P06746 1/20 0.67
ADRA1A P35348 1/20 0.67
BLM P54132 1/20 0.67
TK1 P04183 3/20 0.43
TYMP P19971 2/20 0.43
BCHE P06276 5/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3477 0.87 TK1 (0.43) ALDH1A1LMNAALBPOLBADRA1A
SCHEMBL28129115 0.87 TK1 (0.43) ALDH1A1LMNAALBPOLBADRA1A
Hydrochloric Acid SCHEMBL28100272 0.85 TK1 (0.42) ALDH1A1LMNAALBPOLBADRA1A
Phosphoric Acid SCHEMBL9392093 0.82 TYMP (0.43) ALDH1A1LMNAALBPOLBADRA1A
Phosphoric Acid SCHEMBL3092301 0.82 TYMP (0.43) ALDH1A1LMNAALBPOLBADRA1A
SCHEMBL28839372 0.82 TK1 (0.40) ALDH1A1LMNAALBPOLBADRA1A
Stavudine SCHEMBL3234890 0.82 ALDH1A1 (1.00) ALDH1A1LMNAALBPOLBADRA1A
Stavudine SCHEMBL8540086 0.82 ALDH1A1 (1.00) ALDH1A1LMNAALBPOLBADRA1A
Stavudine SCHEMBL9999805 0.82 ALDH1A1 (1.00) ALDH1A1LMNAALBPOLBADRA1A
Stavudine SCHEMBL18474938 0.82 ALDH1A1 (1.00) ALDH1A1LMNAALBPOLBADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3085377-A1 METHODS OF TREATING VIRAL INFECTIONS Chimerix, Inc. (US) 2016-10-26 EP disclosed
US-8609609-B2 Peptides and methods of use as therapeutics and screening agents NORTH CAROLINA STATE UNIVERSITY (US) 2013-12-17 US disclosed
EP-2240604-B1 PEPTIDES AND METHODS OF USE AS THERAPEUTICS AND SCREENING AGENTS UNIV NORTH CAROLINA STATE (US) 2012-07-25 EP disclosed
US-20110098215-A1 PEPTIDES AND METHODS OF USE AS THERAPEUTICS AND SCREENING AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-04-28 US disclosed
EP-2240604-A2 PEPTIDES AND METHODS OF USE AS THERAPEUTICS AND SCREENING AGENTS North Carolina State University (US) 2010-10-20 EP disclosed
WO-2009091586-A2 PEPTIDES AND METHODS OF USE AS THERAPEUTICS AND SCREENING AGENTS NORTH CAROLINA STATE UNIVERSITY (US) 2009-07-23 WO disclosed